Figure 3

SDS-PAGE analysis of the hydrolytic activities of recombinant ORF1188 protein against rituximab and RNase B. Rituximab (A) or RNase B (B) was incubated separately with Endo-S, Endo-CC1, ORF1188 proteins overnight. Reaction mixtures were then subjected to SDS-PAGE analysis using either a 12% (for rituximab) or a 15% (for RNase B) acrylamide gel. Untreated rituximab (IgG) and RNase B were used as negative controls in (A) and (B), respectively. After SDS-PAGE, gels were stained with CBB. In (A), the heavy chain of IgG migrated as at approximately 50 kDa protein.